OtherJun 15, 2026
SMA Europe launches the Annual report 2025
We are pleased to launch SMA Europe’s Annual report 2025.
SMA Newsroom
Jun 12, 2026
Community Letter from NMD Pharma: completion of its Phase 2 SYNAPSE-SMA clinical trial of ignaseclant (formerly NMD670)
May 14, 2026
Community Update: FDA accepts to review Biologics License Application for apitegromab
FDA accepts to review Biologics License Application for apitegromab
Apr 24, 2026
Community Update: Novartis receives EMA CHMP positive opinion for Itvisma
Novartis receives EMA CHMP positive opinion for Itvisma, gene therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA).